BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, December 15, 2025
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 26, 2008
View Archived Issues
Bad News on Phase III Trial Sends Medicure Plummeting
Read More
Satraplatin Reverberations: GPC Cutting 63 Positions
Read More
Cypress Buys into Personalized Medicine with $75M Proprius Deal
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Financings Roundup
Read More
Immtech Drops Pafuramidine on Safety Concerns, Stock Tumbles
Shares of Immtech Pharmaceuticals Inc. plunged for the second time in two months after the company said it was discontinuing development of lead drug pafuramidine due to safety concerns. (BioWorld Today)
Read More
GTx Good News on ADT Gives its Stock a 36 Percent Boost
Read More
